- Home
- PHAR vs TWO Comparison
PHAR vs TWO Comparison
Compare PHAR & TWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- TWO
- Stock Information
- Founded
- PHAR 1988
- TWO 2009
- Country
- PHAR Netherlands
- TWO United States
- Employees
- PHAR N/A
- TWO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- TWO Real Estate Investment Trusts
- Sector
- PHAR Health Care
- TWO Real Estate
- Exchange
- PHAR Nasdaq
- TWO Nasdaq
- Market Cap
- PHAR 951.7M
- TWO 1.1B
- IPO Year
- PHAR N/A
- TWO 2009
- Fundamental
- Price
- PHAR $14.34
- TWO $9.84
- Analyst Decision
- PHAR Strong Buy
- TWO Buy
- Analyst Count
- PHAR 3
- TWO 8
- Target Price
- PHAR $30.00
- TWO $12.50
- AVG Volume (30 Days)
- PHAR 14.9K
- TWO 1.9M
- Earning Date
- PHAR 10-23-2025
- TWO 10-27-2025
- Dividend Yield
- PHAR N/A
- TWO 15.69%
- EPS Growth
- PHAR N/A
- TWO N/A
- EPS
- PHAR N/A
- TWO N/A
- Revenue
- PHAR $339,836,000.00
- TWO $257,735,000.00
- Revenue This Year
- PHAR $17.44
- TWO N/A
- Revenue Next Year
- PHAR $8.46
- TWO N/A
- P/E Ratio
- PHAR N/A
- TWO N/A
- Revenue Growth
- PHAR 22.44
- TWO N/A
- 52 Week Low
- PHAR $7.31
- TWO $9.50
- 52 Week High
- PHAR $17.08
- TWO $14.28
- Technical
- Relative Strength Index (RSI)
- PHAR 50.39
- TWO 47.92
- Support Level
- PHAR $14.22
- TWO $9.60
- Resistance Level
- PHAR $16.29
- TWO $10.22
- Average True Range (ATR)
- PHAR 0.50
- TWO 0.18
- MACD
- PHAR -0.13
- TWO -0.00
- Stochastic Oscillator
- PHAR 37.30
- TWO 38.81
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.